Valuation: StimCell Energetics Inc.

Market Cap 4.65M 4.13M 3.86M 3.52M 6.63M 447M 6.69M 46.68M 18.09M 229M 17.46M 17.08M 734M P/E 2027 *
-11x
P/E 2028 * -
Enterprise Value 4.65M 4.13M 3.86M 3.52M 6.63M 447M 6.69M 46.68M 18.09M 229M 17.46M 17.08M 734M EV / Sales 2027 *
-
EV / Sales 2028 * 7.75x
Free-Float
28.33%
Yield 2027 *
-
Yield 2028 * -
1 day-10.93%
1 month-21.43%
3 months-29.94%
6 months-34.36%
Current year-45.00%
1 month 0.22
Extreme 0.22
0.25
Current year 0.18
Extreme 0.18
0.48
1 year 0.18
Extreme 0.18
0.48
3 years 0
Extreme 0.0015
3.42
5 years 0
Extreme 1.4E-5
13.97
10 years 0
Extreme 1.4E-5
25.35
Manager TitleAgeSince
Chief Executive Officer 56 11/12/2023
Director of Finance/CFO 48 23/11/2014
Director TitleAgeSince
Chairman 74 25/02/2024
Director/Board Member 62 07/06/2020
Director/Board Member 56 11/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
18/12/25 Sell

Director

16,667 0.0807%
17/03/25 Tax

Director

60,841,472 -
25/02/25 Buy 15,000 0.0757%
Change 5-day change 1-year change 3-year change Capi.($)
-10.93%-.--%-40.36%-52.69% 4.65M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -1.30%-0.53%+43.33%+110.42% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2027 *2028 *
Net sales - 600K 533K 498K 454K 855K 57.68M 863K 6.02M 2.33M 29.49M 2.25M 2.2M 94.63M
Net income -510K -453K -423K -385K -727K -49.03M -734K -5.12M -1.98M -25.06M -1.91M -1.87M -80.44M -
Net Debt - -
Logo StimCell Energetics Inc.
StimCell Energetics Inc. is a biotech company, which is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System. eBalance is a non-invasive, fully automated microcurrent electrotherapy system administering pre-programmed algorithms through the epidermis at the touch of a button to help you gain optimal wellness and reduce pain. Its eBalance represents a monumental stride in the realm of medical technology designed to rejuvenate and re-energize the human body at a cellular level. The operation of eBalance is an intricate process of precision engineering and human biology.
Employees
1
Date Price Change Volume
29/09/26 US$0.000000 - 103

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STME Stock